B of A Securities Maintains Underperform on Talis Biomedical, Lowers Price Target to $1.5
B of A Securities analyst Derik De Bruin maintains Talis Biomedical (NASDAQ:TLIS) with a Underperform and lowers the price target from $3 to $1.5.
Manufacturing Bottlenecks Hit Launch Of Talis’ FDA-Approved COVID-19 Test
Talis Biomedical Corp (NASDAQ: TLIS) said that it had
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 109 companies set new 52-week lows.
B of A Securities Downgrades Talis Biomedical to Underperform, Announces $3 Price Target
B of A Securities analyst Derik De Bruin downgrades Talis Biomedical (NASDAQ:TLIS) from Neutral to Underperform and announces $3 price target.
80 Biggest Movers From Yesterday
Gainers
BIMI International Medical Inc. (NASDAQ: BIMI) shares surged 55% to close at $1.00 on Tuesday as the company reported a narrower Q3 loss.